Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 12Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Pancreatic Neoplasms 3Neoplasms 3Melanoma 3Carcinoma, Non-Small-Cell Lung 3Uterine Neoplasms 2Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Ovarian Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urologic Neoplasms 1Thrombocytosis 1

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Palliative Care 1Massage 1Lysine Acetyltransferase 5 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pulmonary Disease, Chronic Obstructive × Immunoglobulin G × Genitourinary × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡